Transdermal Insulin Response In Healthy Volunteers

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 12, 2021

Primary Completion Date

November 15, 2021

Study Completion Date

November 15, 2021

Conditions

Pharmacodynamic Response to Small Doses of Insulin

Interventions

COMBINATION_PRODUCT

Human insulin

Human Insulin from recombinant source delivered in a solution capable of enabling transdermal delivery formulated at 100 IU/mL of delivery vehicle.

Trial Locations (1)

Langford Research Institute, Palm Beach Gardens

All Listed Sponsors

collaborator

Langford Research Institute, Inc.

INDUSTRY

lead

Transdermal Delivery Solutions Corp

INDUSTRY

NCT04857320 - Transdermal Insulin Response In Healthy Volunteers | Biotech Hunter | Biotech Hunter